Tag Archives: Indian pharmaceutical industry

Delhi High Court, diabetes FDC ban, Type II Diabetes Mellitus, fixed dose combination drugs, Glimepiride Pioglitazone Metformin, Drugs and Cosmetics Act 1940, Section 26A, DTAB recommendations, pharma regulatory news India, Indian pharmaceutical industry, drug safety regulations, anti-diabetic medicines, pharma manufacturing India, monopoly medicine company in India, pharma contract manufacturing company

Delhi High Court Restores Ban on Certain Type II Diabetes FDCs: Legal, Regulatory, and Industry Implications

[…]

Read More
Import Price Floor on Cards for Critical Pharma Inputs

Import Price Floor on Cards for Critical Pharma Inputs

India is preparing to introduce a minimum import price (MIP) for several essential pharmaceutical raw materials. Th […]

Read More